As the demand for increased levels of evidence grows, so too has the role of Non-Company Sponsored Research (NCSR). This position paper by the MAPS Evidence Generation Domain provides key considerations to ensure NCSR delivers strategic value.
Many Medical Affairs professionals lack holistic understanding of the business context in which medicines are developed or even view commercial aspects as incompatible with scientific and medical values. This paper provides fundamental understanding of business priorities, empowering Medical Affairs to contribute effectively to enterprise-wide
Guide and templates for Medical Affairs input into MedTech Health Hazard Assessment
Guide and templates for Medical Affairs input into MedTech Health Hazard Assessment
The objective of this article is to discuss the paradigm shift in how companies plan for and deliver on the “long tail” of a drug’s impact even after Loss of Exclusivity (LoE) – a process known as lifecycle management (LCM).
